Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 3
Submit an article Journal homepage
301
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry

Diva Baggioa Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Heidelberg, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6327-6069View further author information
ORCID Icon,
Cameron Wellardb School of Public Health and Preventive Medicine, Monash University, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0002-6115-5394View further author information
ORCID Icon,
Eliza Chungb School of Public Health and Preventive Medicine, Monash University, Melbourne, AustraliaView further author information
,
Dipti Talaulikarc Canberra Health, Australian Capital Territory, Canberra, AustraliaView further author information
,
Colm Keaned Princess Alexandra Hospital, Woolloongabba, AustraliaView further author information
,
Stephen Opatb School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia;e Monash Health, Clayton, AustraliaORCID Iconhttps://orcid.org/0000-0002-0308-6458View further author information
ORCID Icon,
Pratyush Girif Royal Adelaide Hospital, Adelaide, AustraliaView further author information
,
Adrian Minsong Peter MacCallum Cancer Centre, Melbourne, Australia;h The Royal Melbourne Hospital, Parkville, AustraliaView further author information
,
Chan Yoon Cheahi Sir Charles Gairdner Hospital, Nedlands, AustraliaORCID Iconhttps://orcid.org/0000-0001-7988-1565View further author information
ORCID Icon,
Tasman Armytagej Gosford Hospital, Gosford, AustraliaView further author information
,
Denise Leek Eastern Health, Box Hill, AustraliaView further author information
,
Geoffrey Chongl Ballarat Regional Integrated Cancer Centre, Ballarat, AustraliaView further author information
,
Anna Johnstonm Royal Hobart Hospital, Hobart, AustraliaView further author information
,
Tara Cochranen Gold Coast University Hospital, Southport, AustraliaView further author information
,
Neil Watersb School of Public Health and Preventive Medicine, Monash University, Melbourne, AustraliaView further author information
,
Nada Hamado St Vincent’s Health, Darlinghurst, AustraliaORCID Iconhttps://orcid.org/0000-0001-7929-1450View further author information
ORCID Icon,
Erica M. Woodb School of Public Health and Preventive Medicine, Monash University, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0001-7527-2340View further author information
ORCID Icon &
Eliza A. Hawkesa Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Australia;b School of Public Health and Preventive Medicine, Monash University, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0002-0376-2559View further author information
ORCID Icon show all
Pages 621-627 | Received 01 Oct 2022, Accepted 06 Dec 2022, Published online: 21 Dec 2022

References

  • Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516.
  • Wang M, Goy A, Martin P, et al. Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy. Blood. 2014;124(21):4471.
  • Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–778.
  • Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–667.
  • Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148–3158.
  • Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577–2585.
  • Loh Z, Salvaris R, Chong G, et al. Evolution of eligibility criteria for diffuse large B‐cell lymphoma randomised controlled trials over 30 years. Br J Haematol. 2021;193(4):741–749.
  • Schilsky RL. Finding the evidence in real-world evidence: moving from data to information to knowledge. J Am Coll Surg. 2017;224(1):1–7.
  • McCulloch R, Lewis D, Crosbie N, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients. Br J Haematol. 2021;193(2):290–298.
  • Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–438.
  • Epperla N, Hamadani M, Cashen AF, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study. Hematol Oncol. 2017;35(4):528–535.
  • Tucker D, Morley N, MacLean P, et al. The 5‐year follow‐up of a real‐world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma. Br J Haematol. 2021;192(6):1035–1038.
  • Anderson MA. Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand lymphoma and related diseases registry. BMC Med Res Methodol. 2022;10:266.
  • Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues; 2008 [Internet]. Geneva, Switzerland: WHO Press. Available from: http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=4002
  • Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):8.
  • National Cancer Institute (U.S.). Common terminology criteria for adverse events : (CTCAE); 2017 [Internet]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5.0.xlsx
  • Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745.
  • Sharman J, Kabadi SM, Clark J, et al. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Br J Haematol. 2021;192(4):737–746.
  • Winqvist M, Asklid A, Andersson P, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016;101(12):1573–1580.
  • Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3(12):1799–1807.
  • Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.